DUBLIN – Morphosys AG and Galapagos NV are splitting $111 million up front and could share up to $1 billion more in development, regulatory and commercial milestones from a licensing deal with Novartis AG on their jointly developed interleukin-17C (IL-17C) inhibitor, MOR-106, for atopic dermatitis and potentially other indications.